Human iPS cells attract worldwide attention as a promising cell source for regenerative medicine, drug discovery, and disease research. On the other hand, the stable mass production of target cells is indispensable for their practical use and acceleration of research and development. In our industry-academia collaborative research, our research group has successfully performed in high-density mass culture of human iPS cell aggregates by low-share stress agitation. In addition to hardware development, we have succeeded in mass production of undifferentiated human iPS cells, and iPS-derived cardiomyocytes, pancreatic islet cells, and thyroid follicular cells. By using these cell sources, we are vigorously advancing research in tissue engineering and regenerative medicine.
